Interview: Valters Bolēvics – Executive Director, The Association of International Research-based Pharmaceutical Manufacturers (SIFFA), Latvia

23.02.2018
SIFFA’s Valters Bolēvics discusses Latvia’s competitiveness in embracing medical innovations, current healthcare reforms, and the country’s enduring potential as a pharmaceutical investment destination. The Association of International Research-based Pharmaceutical Manufacturers (SIFFA) was initially founded in 1996 to act as a united voice for five multinationals that had penetrated the local market. Could you please introduce the scope of your activities today?
"The big advantage of Latvia is our geographical positioning right in the middle of the Baltics."
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Baltics, Latvia, SIFFA, Association, Innovation, Regulatory Reform, Healthcare, Market Access

Related Interviews

Interview: Inese Bolmane – Business Development Manager, Cilmes Šūnu…

Inese Bolmane, business development manager at Latvian stem cell bank Cilmes Šūnu Banka, explains the basic rationale behind stem cell banking and what differentiates Cilmes Šūnu Banka from the competition.…

Interview: Vasily Bankovsky – Chairman of the Board & Founder; Svetlana…

Vasily and Svetlana Bankovsky, founders of Biosan, talk about the company’s philosophy to develop modern, exciting personal products for sample preparation in the field of genomics, proteomics and cellomics and…

Interview: Anda Čakša – Minister of Health, Latvia

Anda Čakša, Latvia’s minister of health since 2016, discusses her current priorities, regulatory reform, areas of strengths and weaknesses in the nation’s healthcare infrastructure, e-health, and combating the threat of…

Related Articles

A Pivot Towards Recruitment Process Outsourcing (RPO) in the Baltics

As the Lithuanian market matures, profound shifts have been taking place in the arena of human resources and how drug developers go about identifying, acquiring and retaining the personnel they…

Diabetes in Lithuania: A Silent Crisis

With over 120,000 people whose lives are affected by the disease in Lithuania; diabetes stands as one of the country’s major health issues today. Furthermore, as Marijus Valatka, general manager…

Lithuania’s Biotech Potential

Lithuania’s biotech sector has grown by between 20 and 25 percent over the last five years and accounts for over one percent of the entire country’s GDP. Key industry stakeholders…

Latest Report

Denmark Pharma Report 2021

Related Content

Baltics
Latvia
SIFFA
Association
Innovation
Regulatory Reform
Healthcare